Diaceutics PLC
DIUXFOTCHealthcare● Active
$2.00
+$0.00(+0.00%)
Market Cap$169258896
P/E Ratio—
52W High$2.51
52W Low$1.3672
Diaceutics PLC (DIUXF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DIUXF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 26, 2026EPS Actual
$0.04
Est. $0.04 · +0.0%
Revenue
$0.03B
Est. $0.03B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 26, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
DIUXF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.12
Rev. $4.47B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.12
Rev. Est.$4.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 29, 2026 | -$0.04 | — | — | — | $0.02B | — |
| — Q2 FY2026 | May 26, 2026 | $0.04 | $0.04 | +0.0% | $0.03B | $0.03B | +0.0% |
| ▼ Q3 FY2025 | Sep 23, 2025 | -$0.04 | -$0.04 | -3.3% | $0.02B | $0.02B | -0.3% |
| ▼ Q2 FY2025 | May 13, 2025 | $0.03 | $0.01 | -50.9% | $0.02B | $0.02B | -0.2% |
| ▲ Q3 FY2024 | Sep 17, 2024 | -$0.05 | -$0.04 | +19.4% | $0.02B | $0.02B | +0.3% |
| ▼ Q2 FY2024 | Jun 24, 2024 | $0.00 | -$0.00 | -185.6% | $0.02B | $0.02B | -1.2% |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.02 | — | $0.01B | $0.01B | +0.0% |
| ▲ Q4 FY2022 | Dec 31, 2022 | $0.02 | $0.02 | +27.2% | $0.01B | $0.02B | -2.6% |
Q3 FY2026
Sep 29, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 26, 2026
EPS Actual
$0.04
EPS Est.
$0.04
EPS Surpr.
+0.0%
Revenue
$0.03B
Q3 FY2025
Sep 23, 2025Miss
EPS Actual
-$0.04
EPS Est.
-$0.04
EPS Surpr.
-3.3%
Revenue
$0.02B
Q2 FY2025
May 13, 2025Miss
EPS Actual
$0.01
EPS Est.
$0.03
EPS Surpr.
-50.9%
Revenue
$0.02B
Q3 FY2024
Sep 17, 2024Beat
EPS Actual
-$0.04
EPS Est.
-$0.05
EPS Surpr.
+19.4%
Revenue
$0.02B
Q2 FY2024
Jun 24, 2024Miss
EPS Actual
-$0.00
EPS Est.
$0.00
EPS Surpr.
-185.6%
Revenue
$0.02B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2022
Dec 31, 2022Beat
EPS Actual
$0.02
EPS Est.
$0.02
EPS Surpr.
+27.2%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.04 | $0.04 | $0.04 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2024 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 26, 2026 | +0.0% | $1.67 | $2.05 | +22.75% |
| ▼ Q3 FY2025 | Sep 23, 2025 | -3.3% | $1.37 | $1.37 | +0.00% |
| ▼ Q2 FY2025 | May 13, 2025 | -50.9% | $1.37 | $1.37 | +0.00% |
| ▲ Q3 FY2024 | Sep 17, 2024 | +19.4% | $1.37 | $1.37 | +0.00% |
| ▼ Q2 FY2024 | Jun 24, 2024 | -185.6% | $1.37 | $1.37 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $1.12 | $1.12 | +0.00% |
| ▲ Q4 FY2022 | Dec 31, 2022 | +27.2% | $1.12 | $1.12 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $1.12 | $1.12 | +0.00% |
Q2 FY2026+22.75%
Report Date
May 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.67
Price After
$2.05
Q3 FY2025+0.00%
Report Date
Sep 23, 2025
EPS Beat/Miss
-3.3%
Price Before
$1.37
Price After
$1.37
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
-50.9%
Price Before
$1.37
Price After
$1.37
Q3 FY2024+0.00%
Report Date
Sep 17, 2024
EPS Beat/Miss
+19.4%
Price Before
$1.37
Price After
$1.37
Q2 FY2024+0.00%
Report Date
Jun 24, 2024
EPS Beat/Miss
-185.6%
Price Before
$1.37
Price After
$1.37
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.12
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
+27.2%
Price Before
$1.12
Price After
$1.12
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.12
Avg Beat Reaction+7.58%
Avg Miss Reaction+0.00%
Beat Rate3 / 8 quarters
Largest Move+22.75% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DIUXF ends December
Diaceutics PLC (DIUXF) most recently reported earnings on May 26, 2026 for Q2 FY2026, posting EPS of $0.04 (in line with the analyst consensus of $0.04). The next DIUXF earnings date is expected around September 1, 2026.
Each quarter, investors track DIUXF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DIUXF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DIUXF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DIUXF earnings · 4 questionsDiaceutics PLC's next earnings report is expected around September 1, 2026. DIUXF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DIUXF historically reports after market close (AMC).
DIUXF earnings datewhen is DIUXF earningsDIUXF next earnings datewhen does DIUXF report earningsDIUXF earnings calendar
▸ Source: FMP · Diaceutics PLC SEC filings · US GAAP · Diaceutics PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026